Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The is a randomized control study for newly-diagnosed myeloma patients 18-65 year old. All
patients will receive 4 cycles of velcade and Dexamethasone as front-line therapy. Then
patients will be randomized into standard group which will receive a single autologous
hematopoietic stem cell transplantation with standard conditioning of melphalan 200mg/m2 and
the study group which will receive single autologous hematopoietic stem cell transplantation
with conditioning of melphalan 200mg/m2 + velcade followed by 3 more cycles of velcade alone
as consolidation.